U.S. Immunoassay Market Size, Share & Trends Analysis Report By Product (Reagent & Kits, Analyzers/Instruments), By Technology (RIA, ELISA), By Application, By Specimen, By End-use, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
U.S. Immunoassay Market Growth & Trends
The U.S. immunoassay market is anticipated to reach USD 12.25 billion by 2030 and is projected to grow at a CAGR of 2.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing incidence of chronic and infectious diseases and rising demand for early detection of diseases are the major factors contributing to the market growth. According to the International Agency for Research on Cancer, 19,292,789 cancer cases were reported in 2020 and are expected to reach 50,550,287 by 2025. Breast, lung, colorectum, prostate, and stomach are the most common cancers reported.
The rising geriatric population is a significant factor driving the market growth in the U.S. As more individuals reach retirement age and require medical care, the demand for diagnostic tests such as immunoassays is expected to rise. Furthermore, technological advancements such as automation, miniaturization, point-of-care testing devices, and advanced detection technologies are key drivers of the immunoassay market. These innovations have revolutionized immunoassay techniques, making them more efficient, reliable, and accessible for a wide range of applications in healthcare and research.
The growing adoption of immunoassay tests in clinical diagnostics and research laboratories has positively impacted the U.S. market by driving market expansion, fostering innovation in assay development, and improving patient outcomes through early and accurate diagnosis.
U.S. Immunoassay Market Report Highlights
U.S. Immunoassay Market Growth & Trends
The U.S. immunoassay market is anticipated to reach USD 12.25 billion by 2030 and is projected to grow at a CAGR of 2.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing incidence of chronic and infectious diseases and rising demand for early detection of diseases are the major factors contributing to the market growth. According to the International Agency for Research on Cancer, 19,292,789 cancer cases were reported in 2020 and are expected to reach 50,550,287 by 2025. Breast, lung, colorectum, prostate, and stomach are the most common cancers reported.
The rising geriatric population is a significant factor driving the market growth in the U.S. As more individuals reach retirement age and require medical care, the demand for diagnostic tests such as immunoassays is expected to rise. Furthermore, technological advancements such as automation, miniaturization, point-of-care testing devices, and advanced detection technologies are key drivers of the immunoassay market. These innovations have revolutionized immunoassay techniques, making them more efficient, reliable, and accessible for a wide range of applications in healthcare and research.
The growing adoption of immunoassay tests in clinical diagnostics and research laboratories has positively impacted the U.S. market by driving market expansion, fostering innovation in assay development, and improving patient outcomes through early and accurate diagnosis.
U.S. Immunoassay Market Report Highlights
- Reagents & kits led the market with the largest revenue share of 65.82% in 2023 and are expected to grow at the fastest CAGR over the forecast period, owing to the increasing introduction and approval of innovative immunoassay kits
- Based on application, the infectious diseases testing segment led the market with the largest revenue share of 29.55% in 2023, due to increasing demand for immunoassays for early detection of infectious diseases such as HIV, hepatitis, COVID-19, and others
- Based on end-use, the hospital segments held the market with the largest revenue share of 33.01% in 2023. Hospitals are considered primary care facilities for the diagnosis of various diseases, which is driving segment growth
- Based on specimen, the blood segment led the market with the largest revenue share of 43.19% in 2023, owing to the increasing incidence of diseases requiring these blood testing procedures and technological advancements in the segment
- In July 2023, SEKISUI Diagnostics introduced the OSOM COVID-19 Antigen Home Test, made in the U.S. The test can be performed at home and is likely to help detect nucleocapsid protein antigen that results from the SARS-CoV-2 virus
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Technology
1.2.3. Application
1.2.4. End-use
1.2.5. Specimen
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Technology outlook
2.2.3. Application outlook
2.2.4. End-use outlook
2.2.5. Specimen outlook
2.3. Competitive Insights
CHAPTER 3. U.S. IMMUNOASSAY MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Immunoassay Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Legal landscape
3.3.2.6. Environmental landscape
CHAPTER 4. U.S. IMMUNOASSAY MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Immunoassay Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
4.4.1. Reagents & kits
4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2. ELISA reagents & kits
4.4.1.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.3. Rapid test reagents & kits
4.4.1.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.4. ELISPOT reagents & kits
4.4.1.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.5. Western blot reagents & kits
4.4.1.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.6. Other reagents & kits
4.4.1.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Analyzers/instruments
4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.2. Open ended systems
4.4.2.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.3. Closed ended systems
4.4.2.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Software & Services
4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. U.S. IMMUNOASSAY MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1. Technology Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Immunoassay Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
5.4.1. Radioimmunoassay (RIA)
5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Enzyme Immunoassays (EIA)
5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.2. Chemiluminescence Immunoassays (CLIA)
5.4.2.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.3. Fluorescence Immunoassays (FIA)
5.4.2.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3. Rapid test
5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.4. Others
5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. U.S. IMMUNOASSAY MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Application Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Immunoassay Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
6.4.1. Therapeutic drug monitoring
6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.2. Oncology
6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. Cardiology
6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.4. Endocrinology
6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.5. Infectious disease testing
6.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.6. Autoimmune diseases
6.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.7. Others
6.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 7. U.S. IMMUNOASSAY MARKET: END-USE ESTIMATES & TREND ANALYSIS
7.1. End-use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. U.S. Immunoassay Market by End-use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
7.4.1. Hospitals
7.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2. Blood banks
7.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3. Clinical laboratories
7.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4. Pharmaceutical and biotech companies
7.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5. Academic research centers
7.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.6. Others
7.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 8. U.S. IMMUNOASSAY MARKET: SPECIMEN ESTIMATES & TREND ANALYSIS
8.1. Specimen Market Share, 2023 & 2030
8.2. Segment Dashboard
8.3. U.S. Immunoassay Market by Specimen Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
8.4.1. Blood
8.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.2. Saliva
8.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.3. Urine
8.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.4. Other specimens
8.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 9. U.S. IMMUNOASSAY MARKET: REGION ESTIMATES & TREND ANALYSIS
9.1. Regional Market Share, 2023 & 2030
9.2. U.S. Immunoassay Market by Region Outlook
9.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
9.3.1. West
9.3.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.2. Midwest
9.3.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.3. Northeast
9.3.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.4. Southwest
9.3.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.5. Southeast
9.3.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company heat map analysis, 2023
10.4. Company Profiles
10.4.1. F. Hoffmann-La Roche AG
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Abbott Laboratories
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. Siemens Healthineers
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Danaher Corporation
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Thermo Fisher Scientific
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Bio-Rad Laboratories
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Beckman Coulter (a subsidiary of Danaher)
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Sysmex Corporation
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Product benchmarking
10.4.8.4. Strategic initiatives
10.4.9. DiaSorin
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Product benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Agilent Technologies
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Product benchmarking
10.4.10.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Technology
1.2.3. Application
1.2.4. End-use
1.2.5. Specimen
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Technology outlook
2.2.3. Application outlook
2.2.4. End-use outlook
2.2.5. Specimen outlook
2.3. Competitive Insights
CHAPTER 3. U.S. IMMUNOASSAY MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Immunoassay Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Legal landscape
3.3.2.6. Environmental landscape
CHAPTER 4. U.S. IMMUNOASSAY MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Immunoassay Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
4.4.1. Reagents & kits
4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2. ELISA reagents & kits
4.4.1.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.3. Rapid test reagents & kits
4.4.1.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.4. ELISPOT reagents & kits
4.4.1.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.5. Western blot reagents & kits
4.4.1.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.6. Other reagents & kits
4.4.1.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Analyzers/instruments
4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.2. Open ended systems
4.4.2.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.3. Closed ended systems
4.4.2.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Software & Services
4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. U.S. IMMUNOASSAY MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1. Technology Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Immunoassay Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
5.4.1. Radioimmunoassay (RIA)
5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Enzyme Immunoassays (EIA)
5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.2. Chemiluminescence Immunoassays (CLIA)
5.4.2.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.3. Fluorescence Immunoassays (FIA)
5.4.2.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3. Rapid test
5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.4. Others
5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. U.S. IMMUNOASSAY MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Application Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Immunoassay Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
6.4.1. Therapeutic drug monitoring
6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.2. Oncology
6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. Cardiology
6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.4. Endocrinology
6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.5. Infectious disease testing
6.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.6. Autoimmune diseases
6.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.7. Others
6.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 7. U.S. IMMUNOASSAY MARKET: END-USE ESTIMATES & TREND ANALYSIS
7.1. End-use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. U.S. Immunoassay Market by End-use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
7.4.1. Hospitals
7.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2. Blood banks
7.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3. Clinical laboratories
7.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4. Pharmaceutical and biotech companies
7.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5. Academic research centers
7.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.6. Others
7.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 8. U.S. IMMUNOASSAY MARKET: SPECIMEN ESTIMATES & TREND ANALYSIS
8.1. Specimen Market Share, 2023 & 2030
8.2. Segment Dashboard
8.3. U.S. Immunoassay Market by Specimen Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
8.4.1. Blood
8.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.2. Saliva
8.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.3. Urine
8.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.4. Other specimens
8.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 9. U.S. IMMUNOASSAY MARKET: REGION ESTIMATES & TREND ANALYSIS
9.1. Regional Market Share, 2023 & 2030
9.2. U.S. Immunoassay Market by Region Outlook
9.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
9.3.1. West
9.3.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.2. Midwest
9.3.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.3. Northeast
9.3.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.4. Southwest
9.3.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
9.3.5. Southeast
9.3.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company heat map analysis, 2023
10.4. Company Profiles
10.4.1. F. Hoffmann-La Roche AG
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Abbott Laboratories
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. Siemens Healthineers
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Danaher Corporation
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Thermo Fisher Scientific
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Bio-Rad Laboratories
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Beckman Coulter (a subsidiary of Danaher)
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Sysmex Corporation
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Product benchmarking
10.4.8.4. Strategic initiatives
10.4.9. DiaSorin
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Product benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Agilent Technologies
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Product benchmarking
10.4.10.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviations
Table 2 U.S. immunoassay market, by product, 2018 - 2030 (USD Million)
Table 3 U.S. immunoassay market, by technology, 2018 - 2030 (USD Million)
Table 4 U.S. immunoassay market, by application, 2018 - 2030 (USD Million)
Table 5 U.S. immunoassay market, by end use, 2018 - 2030 (USD Million)
Table 6 U.S. immunoassay market, by specimen, 2018 - 2030 (USD Million)
Table 7 U.S. immunoassay market, by region, 2018 - 2030 (USD Million)
Table 1 List of abbreviations
Table 2 U.S. immunoassay market, by product, 2018 - 2030 (USD Million)
Table 3 U.S. immunoassay market, by technology, 2018 - 2030 (USD Million)
Table 4 U.S. immunoassay market, by application, 2018 - 2030 (USD Million)
Table 5 U.S. immunoassay market, by end use, 2018 - 2030 (USD Million)
Table 6 U.S. immunoassay market, by specimen, 2018 - 2030 (USD Million)
Table 7 U.S. immunoassay market, by region, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. immunoassay market: Market outlook
Fig. 9 U.S. immunoassay competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. immunoassay market driver impact
Fig. 14 U.S. immunoassay market restraint impact
Fig. 15 U.S. immunoassay market: Product movement analysis
Fig. 16 U.S. immunoassay market: Product outlook and key takeaways
Fig. 17 Reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Elisa reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Rapid test reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Elispot reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Western blot reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Other reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Analyzers/Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Open ended systems market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Closed ended systems market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Software & services market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 U.S. immunoassay Market: Technology movement Analysis
Fig. 28 U.S. immunoassay market: Technology outlook and key takeaways
Fig. 29 Radioimmunoassay (RIA) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Enzyme Immunoassays (EIA) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Chemiluminescence Immunoassays (CLIA) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Fluorescence Immunoassays (FIA) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Rapid test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 U.S. immunoassay market: Application movement analysis
Fig. 36 U.S. immunoassay market: Application outlook and key takeaways
Fig. 37 Therapeutic drug monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Cardiology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Endocrinology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Infectious disease testing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Autoimmune diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 U.S. immunoassay market: End-use movement analysis
Fig. 45 U.S. immunoassay market: End-use outlook and key takeaways
Fig. 46 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Blood banks market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Clinical laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Pharmaceutical and biotech companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Academic research centers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 U.S. immunoassay market: Specimen movement analysis
Fig. 53 U.S. immunoassay market: Specimen outlook and key takeaways
Fig. 54 Blood market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Saliva market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Urine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Other specimens market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 U.S. immunoassay market: Regional movement analysis
Fig. 59 U.S. immunoassay market: Regional outlook and key takeaways
Fig. 60 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. immunoassay market: Market outlook
Fig. 9 U.S. immunoassay competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. immunoassay market driver impact
Fig. 14 U.S. immunoassay market restraint impact
Fig. 15 U.S. immunoassay market: Product movement analysis
Fig. 16 U.S. immunoassay market: Product outlook and key takeaways
Fig. 17 Reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Elisa reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Rapid test reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Elispot reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Western blot reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Other reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Analyzers/Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Open ended systems market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Closed ended systems market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Software & services market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 U.S. immunoassay Market: Technology movement Analysis
Fig. 28 U.S. immunoassay market: Technology outlook and key takeaways
Fig. 29 Radioimmunoassay (RIA) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Enzyme Immunoassays (EIA) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Chemiluminescence Immunoassays (CLIA) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Fluorescence Immunoassays (FIA) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Rapid test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 U.S. immunoassay market: Application movement analysis
Fig. 36 U.S. immunoassay market: Application outlook and key takeaways
Fig. 37 Therapeutic drug monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Cardiology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Endocrinology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Infectious disease testing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Autoimmune diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 U.S. immunoassay market: End-use movement analysis
Fig. 45 U.S. immunoassay market: End-use outlook and key takeaways
Fig. 46 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Blood banks market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Clinical laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Pharmaceutical and biotech companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Academic research centers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 U.S. immunoassay market: Specimen movement analysis
Fig. 53 U.S. immunoassay market: Specimen outlook and key takeaways
Fig. 54 Blood market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Saliva market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Urine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Other specimens market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 U.S. immunoassay market: Regional movement analysis
Fig. 59 U.S. immunoassay market: Regional outlook and key takeaways
Fig. 60 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
